EVs fused with interleukin have been promising approaches for drug delivery systems and acquire antitumor potential as demonstrated in a study that evaluated the overexpression of the IL-3 receptor (IL3R), in chronic myeloid leukemia (CML) through the genetically engineering of HEK293T cells to produce IL-3 fused EVs. This evidence concerns the gene IL3 and chronic myelogenous leukemia, BCR-ABL1 positive.